Job Trends
Rampart Bioscience was working on a platform to deliver gene therapies without the need for viral vectors.
Labor Market Reports
BioSpace’s Q3 2025 U.S. Life Sciences Job Market Report reveals a turbulent quarter for biopharma hiring, with record declines in job postings, rising layoffs, and cautious employer sentiment shaping the industry’s employment landscape.
BioSpace data show biopharma professionals faced increased competition for fewer employment opportunities during the second quarter of 2025, with increased pressure from further layoffs.
Establishing trust through thought leadership is no longer optional in today’s cautious biopharma market. Learn how strategic insights and targeted outreach can turn awareness into high-converting leads.
Now Hiring
Looking for a new opportunity in New Jersey? These nine companies have open roles that could be a great fit for you.
Job listings in the area have ticked up in the last month. These seven companies are hiring in South San Francisco right now, including scientist and clinical roles.
Looking for a biopharma job in New York? Check out the BioSpace list of eight companies hiring life sciences professionals like you.
Career Advice
Clarity on employment terms is essential to protect careers. In this column, Kaye/Bassman’s Michael Pietrack speaks to employment attorney Howard Matalon, JD, partner at OlenderFeldman, on how to evaluate the fine print of an employment agreement.
THE LATEST
About 200 of the job cuts will be in Massachusetts, the remaining in Connecticut.
Medtronic’s building permit for the new facility is valued at $900,000, with the listed architect as Thoda & Associates.
A look at why investors should stock up on Amgen, Celldex Therapeutics, and Novavax soon.
The latest collaborations bring the total number of strategic transactions executed by J&J Innovation to more than 350 since its establishment in 2012.
Shares of TiGenix shot up more than 72 percent in pre-market trading after the deal was announced.
Takeda CEO Christophe Weber is sticking to his game plan of actively hunting deals that will expand its global presence and create a stronger international profile.
Pfizer will use Arvinas’ proprietary PROTAC Platform to create small molecule therapeutics aimed at degrading disease-causing cellular proteins.
Allergan will cut about 5 percent of its workforce, as the company looks to cut costs due to increased pipeline competition and loss of exclusivity on some products.
The entire 1.2 million-square-feet facility is expected to be finished in 2030.
Celgene has been unloading some of its shares in two of its investments, CRISPR Therapeutics and Atara Biotherapeutics.